FDA Approved: AMJEVITA — Supplemental Application (Nuvaila Limited)

View source ↗

Summary

The FDA approved a supplemental application for AMJEVITA (adalimumab-atto) submitted by Nuvaila Limited.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Axial Spondyloarthritis
• Crohn Disease
• Hidradenitis Suppurativa
• Plaque Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis

Drugs mentioned

• AMJEVITA (adalimumab-atto)

Snippet

SUPPL AP for AMJEVITA (ADALIMUMAB-ATTO)